Gilead Sciences, Inc. (GILD)
$147.92-1.67%Close
SELLBULL · day 3
Key stats
Short interest · FINRA settlement 2026-09-30
52-week IV14.6%–95.3%
- Market cap
- $183.7B
- Beta
- 0.33
- Div yield
- 2.20%
- P/E (TTM)
- -56.89
- IV-%ile
- 83
- IV ATM
- 35.3%
- Short % float
- 1.76%
- Days to cover
- 3.4
- SI change
- +19.3%
- 1W
- +2.56%
- 1M
- +1.60%
- vs SPY 1W
- +2.70%
- vs SPY 1M
- -0.91%
Industry peers
FMP comparable companies · ranked by market cap
- LLYBUYEli Lilly and Company$1.1TRECOVERYQ 21$1179.27-1.36%
- JNJSELLJohnson & Johnson$630.0BBEARQ 22$261.44-5.73%
- ABBVBUYAbbVie Inc.$488.5BBULLQ 29$276.47-2.40%
- MRKSELLMerck & Co., Inc.$359.6BBEARQ 11$145.60-2.39%
- RHHBYRoche Holding AG$344.8B$54.09
- NVSBUYNovartis AG$273.2BRECOVERYQ 20$143.75-0.99%
- AZNSELLAstraZeneca PLC$246.9BRECOVERYQ 20$159.20-1.59%
- PFESELLPfizer Inc.$161.2BBULLQ 13$28.28-0.11%
- SNYSELLSanofi$96.2BBEARQ 11$40.07-1.56%
- GSKSELLGSK plc$93.2BRECOVERYQ 14$46.50-1.39%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 35
- VALUE
- 16
- GROWTH
- 30
- GARP
- 45
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-9.8%
REV YoY-
ROE-16.3%
EPS YoY-
ROA-6.6%
GROSS80
OP-5
NET-11
[VALUATION]
P/E TTM-56.89
P/E FWD16.81
SECTOR PE20.34
INDUSTRY PE10.09
P/B15.54
P/FCF-
EV/EBITDA154.78
EV/EBIT-
PEG1.72
FCF YIELD-
RISK
INT COV-
D/E221.90
ALTMAN Z-
CURR RATIO1.27
ND/EBITDA-
BETA0.33
Company news
FAQ
- What is LOPJLB’s current signal on GILD?
- LOPJLB’s latest quantitative signal on Gilead Sciences, Inc. (GILD) is SELL in a BULL regime. Signals are updated daily.
- What market regime is GILD in?
- Gilead Sciences, Inc. (GILD) is currently classified in the BULL HMM market regime on LOPJLB.
- What does Gilead Sciences, Inc. (GILD) do?
- Gilead Sciences, Inc. is a global biopharmaceutical enterprise, with operations spanning the United States, Europe, and numerous international markets. Its core mission involves discovering, developing, and commercializing innovative medications to address critical health needs. The company's extensive product portfolio encompasses treatments for a variety of severe conditions. For HIV/AIDS, it…